CTRI/2019/02/017724已完成不适用
Evaluation of the Pharmacokinetics of Hydrocortisone after Administration of Hydrocortisone Acetate 25 mg and 45 mg Suppository in Healthy Adult Volunteers
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- To determine the pharmacokinetics (PK) of hydrocortisone following a single rectal administration of hydrocortisone acetate suppository
研究概览
简要总结
Evaluation of the Pharmacokinetics of Hydrocortisone after Administration of Hydrocortisone Acetate 25 mg and 45 mg Suppository in Healthy Adult Volunteers. This is a single-center, single-dose, 2-treatment, 2-period, 1-sequence study to be conducted in 20 healthy adult volunteers. The Primary objective study is to determine the pharmacokinetics (PK) of hydrocortisone following a single rectal administration of hydrocortisone acetate suppository. Hydrocortisone will be quantified in plasma and urine with sensitive, selective, validated liquid chromatography-tandem mass spectrometry (LC’MS/MS) bioanalytical methods.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 55.00 Year(s)（—）
- 性别
- All
入选标准
- •Healthy males or females of any race, 18 55 years (both inclusive) of age at screening
- •BMI of 18.5-30.0 kg/m2 (both inclusive)
- •If a woman of child-bearing potential, have a negative serum pregnancy test at screening and a negative urine pregnancy test at check-in on Day -1
- •From the time of screening until 30 days after the final study visit, subjects must be sexually inactive, sterile or using effective methods of contraception as follows: If the subject is a male with a female sexual partner who is of childbearing potential, the couple is willing to use two effective methods of birth control during the duration of the trial and for 1 month after the final evaluation or early termination.
- •A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
- •All females of childbearing potential must agree to use two effective methods of contraception for the duration of the study and at least 1 month after the final evaluation or early termination.
- •The two forms of birth control authorized are defined as the use of a barrier method of contraception (condom with spermicide) in association with one of the following methods of birth control: bilateral tubal ligation, combined oral contraceptives (estrogens and progesterone), or implanted or injectable contraceptives with a stable dose for at least 1 month prior to check-in on Day -1; hormonal intra uterine device inserted at least 1 month prior to check-in for Period 1 on Day -1
- •Willing to participate in the study, able to understand and likely to complete all study requirements, and willing to provide voluntary informed consent before initiation of any study-related procedures
- •In the opinion of the Principal Investigator, able to fully comply with the study requirements and judged to be healthy on the basis of the medical history and screening procedures (physical examination, vital signs, and safety laboratory test results)
- •Negative test for selected drugs of abuse at Screening visit and check-in on Day -1
- •Negative hepatitis panel and negative Human Immunodeficiency Virus (HIV) antibody test.
排除标准
- •Known hypersensitivity to hydrocortisone or any of the active or inactive ingredients in the drug treatment
- •Female who is pregnant or lactating or is planning a pregnancy during the study or if of child-bearing potential is unwilling to adhere to the methods of contraception detailed above.
- •Any abnormal laboratory value during screening or check-in on Day 1 that, in the opinion of the Principal Investigator, would interfere with the conduct of the study or safety of the subject
- •History or presence of any significant metabolic, allergic, cardiovascular, pulmonary, hepatic, renal, or hematologic (bleeding) disorders
- •History or presence of any significant gastrointestinal disorder (peptic ulcer disease, gastritis or bleeding diathesis, proctitis, colitis, inflammatory bowel disease, lower gastrointestinal bleeding, active hemorrhoids, and history of constipation or diarrhea/frequent bowel movements per day) within 60 days prior to Day 1
- •History or presence of any significant endocrine disorders (including Addison’s Disease, Cushing’s Syndrome, and Cushingoid features)
- •History or presence of any significant immunologic, dermatologic, muscular, neurological, psychiatric, neoplastic, or other disease, which, in the opinion of the Principal Investigator, could interfere with the course of the study or expose the subject to undue risk by participating in this study
- •Currently participating or has participated within 30 days prior to screening, in an investigational drug or device study
- •Inability to fully comply with the study protocol
- •Seated (after at least 5 minutes rest in a sitting position) systolic blood pressure >140 mmHg or <90 mmHg or a diastolic blood pressure >95 mmHg during Screening
- •Heart rate at rest of <50 beats per minute (bpm) or >100 bpm during Screening
- •Subjects who have a history of any of the following will be excluded: i.Allergy to dexamethasone, hydrocortisone, or to any ingredient in the test drugs ii.HIV, hepatitis, or other blood-borne pathogens iii.Liver damage or renal impairment
- •Prior or current rectal corticosteroid treatment within 6 months of screening and treatment
- •Use of any prescription medications/products, or over-the-counter (OTC)/non-prescription preparations (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within the 14 days prior to Day -1 or 5 half-lives, whichever is longer, unless deemed acceptable by the Principal Investigator in consultation with the Sponsor
- •Any significant rectal pathology that, in the opinion of the Principal Investigator or designee, would be a contraindication (or warning) with a hydrocortisone acetate suppository, including rectal obstruction, abscess, perforation, active fungal infection(s) and/or bacterial infection(s)
- •Anal or rectal surgery within the previous 2 years
- •Use of anorectal medications including creams, ointments, suppositories, foams, and enemas or insertion of any medication or object into the rectum from the time of screening through the end of study
- •Receipt of blood products within 2 months prior to Day -1
- •Consumption of alcohol-containing foods or beverages within the 60 hours prior to Day -1 or throughout the study and the consumption of caffeine-containing foods or beverages within the 12 hours prior to Day -1 and throughout the remainder of the study
- •In the Principal Investigator’s opinion, have been on an abnormal diet (for whatever reason) during the 28 days prior to Day -1.
结局指标
主要结局
To determine the pharmacokinetics (PK) of hydrocortisone following a single rectal administration of hydrocortisone acetate suppository
时间窗: Days 3 and 10
次要结局
- To evaluate the metabolite profile of hydrocortisone in urine(To evaluate the safety and tolerability of a single rectal administration of hydrocortisone acetate suppository)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A study to evaluate Pharmacokinetics parameters of Hydrocortisone Acetate 25 mg and 45 mg Suppository in Healthy Adult VolunteersCTRI/2019/02/017724Genus Lifesciences Inc20
招募中
4 期
Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated NeonatesAsphyxiaCirculatory Failure NeonatalHypoxic-Ischemic EncephalopathyHypotensionNCT05836610Semmelweis University50
进行中（未招募）
1 期
Pharmacocinétique de l’Hydrocortisone chez le patient ADdisonien : évaluation de la valeur prédictive de l’ACTH plasmatique pour la titration du traitement substitutif - PHADMedDRA version: 9.1Level: LLTClassification code 10001130Term: Addison's diseaseADDISON'S DISEASEEUCTR2007-005170-30-FRCHU CAE
进行中（未招募）
不适用
Evaluation of the time to cortisol levels required in critical illness (>1000 nmol/l) and safety of hydrocortisone, after subcutaneous injection in patients with chronic primary adrenal insufficiency(Comparison s.c. vs. i.m.)Adrenal insufficiency under chronic glucocorticoid replacementMedDRA version: 14.0Level: PTClassification code 10001130Term: Addison's diseaseSystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 14.0Level: PTClassification code 10052381Term: Primary adrenal insufficiencySystem Organ Class: 10014698 - Endocrine disordersEUCTR2011-002687-25-DEniversity Hospital of Wuerzburg12
已完成
2 期
Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal InsufficiencyPrimary Adrenal InsufficiencyNCT01450930Bruno Allolio12